Abstract: An air treatment device and an air conditioner indoor unit are provided. The air treatment device has an air outlet frame of a purification air duct. The air outlet frame has a ventilation hole and a cooperation hole. A water tank drawer is moveable on the air outlet frame and has two spaced-apart cooperation protrusions on a bottom wall thereof. A safety locking member of the air treatment device has a rotating shaft and a locking member. The rotating shaft is rotatable in the cooperation hole to switch the locking member between a locking position of the locking member and a movement-permitting position of the locking member. At the locking position, the locking member engages the cooperation protrusions to prevent the displacement of the cooperation protrusions. At the movement-permitting position, the locking member is located between the two cooperation protrusions to avoid engagement with the cooperation protrusions.

Abstract: Provided are a method and a system for controlling wind turbine shutdown. The method includes: obtaining, according to a preset sampling period, a grid voltage for a wind turbine, and sending the obtained grid voltage to an converter controller; determining, by the converter controller and based on the grid voltage, an operating condition of a power grid is power outage of power grid; sending, in a case that the power outage of power grid is determined, a signal indicating power outage of power grid to a main controller of a main control system of the wind turbine; and controlling, by the main controller in a case that the signal indicating power outage of power grid is received, a pitch system to perform a variable-rate feathering.

Abstract: The invention provides certain fused pyrazine compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, R1, R3, R4a, R5a, R5b, R6, and the subscript t are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases or disorders which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and disorders and for preparing pharmaceutical s for this purpose.

Abstract: Provided are methods for treating or preventing a fibrotic disease selected from systemic sclerosis, cystic fibrosis, non-alcoholic steatohepatitis, Peyronie's disease, or interstitial lung disease; the method comprising administering a therapeutically effective amount of a compound of Formula (I) (wherein R1, R2, R3, R4, and R5 are as herein described) or a pharmaceutically acceptable salt thereof, to a patient in need of such therapy.

Abstract: This application consists of a method for the synthesis of a type of FER/MOR composite molecular sieve. That method consisting of mixing FER seed crystals, MOR seed crystals, a silicon source, water and an acid or alkali, thus yielding a reaction mixture; by adjusting the proportions of the seed crystals added, the silicon-aluminium proportion, acidity/alkalinity and other reaction conditions, it is possible to obtain a dual phase composite molecular sieve within which the proportions of the crystal phases may be adjusted. In the synthesis process to which the method of this application relates, there is no need to add any organic template, thus reducing the cost of the reaction, in addition to reducing likely environmental pollution, thus having major potential applications.

Abstract: Insulin dimers conjugated to peptides having at least one incretin activity are disclosed.

Abstract: The present disclosure relates to devices and methods for detecting and removing vapor for an imaging acquisition device. A device for detecting and removing vapor may include a first light guide. The first light guide may include a first end to receive a light beam, and a second end to output the light beam at a predetermined angle with respect to a reference plane, so that when the light beam enters a target light transmission media from the first light guide, the light beam substantially perfectly reflects between a first surface and a second surface of the target light transmission media. The first surface and second surface may substantially parallel to the reference plane.

Abstract: The present invention relates to bicyclic himbacine derivatives of the formula or a pharmaceutically acceptable salt thereof wherein: R1 is W is and the remaining variables are described herein. The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ASC, secondary prevention of myocardial infarction or stroke, or PAD.

Abstract: Insulin-incretin conjugates comprising a peptide having agonist activity at the glucagon-like 1 (GLP-1) receptor, the glucagon (GCG) receptor, and/or the gastric inhibitory protein (GIP) receptor conjugated to an insulin molecule having agonist activity at the insulin receptor and use of the conjugates for treatment of metabolic diseases, for example, Type 2 diabetes, are described.

Abstract: A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.

Abstract: A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.

Abstract: A process for the joint preparation of 1,3,3,3-tetrafluoropropene and 2,3,3,3-tetrafluoropropene, comprising: (a) starting materials comprising at least one compound having the structure of formula I, II or III are reacted with hydrogen fluoride, producing 1,2,3-trichloro-3,3-difluoropropene, 1,2,3-trichloro-1,1,2-trifluoropropane, and 1,2,3-trichloro-1,1,3-trifluoropropane; in the compounds of said formulae CF2-mClm?CCl—CHF2-nCln (Formula I), CF3-pClpCHCl?CH2Cl (Formula II), and CF3-xClxCF2-yClyCHF2-zClz (Formula III), m=0, 1, 2; n=1, 2; p=2, 3; x=1, 2, 3; y=1, 2; z=1, 2 and 4?x+y+z?6; (b) the 1,2,3-trichloro-3,3-difluoropropene, 1,2,3-trichloro-1,1,2-trifluoropropane and 1,2,3-trichloro-1,1,3-trifluoropropane undergo dechlorination, producing 3-chloro-3,3-difluoropropyne, 3-chloro-2,3,3-trifluoropropene and 3-chloro-1,3,3-trifluoropropene; and (c) the 3-chloro-3,3-difluoropropyne, 3-chloro-2,3,3-trifluoropropene and 3-chloro-1,3,3-trifluoropropene are reacted with hydrogen fluoride, simultaneously yielding

Abstract: The present invention relates to bicyclic himbacine derivatives of the formula or a pharmaceutically acceptable salt thereof wherein: R1 is W is and the remaining variables are described herein. The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ASC, secondary prevention of myocardial infarction or stroke, or PAD.

Abstract: A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.

Abstract: A process for the joint preparation of 1,3,3,3-tetrafluoropropene and 2,3,3,3-tetrafluoropropene, comprising: (a) starting materials comprising at least one compound having the structure of formula I, II or III is reacted with hydrogen fluoride, producing 1,2,3-trichloro-3,3-difluoropropene, 1,2,3-trichloro-1,1,2-trifluoropropane, and 1,2,3-trichloro-1,1,3-trifluoropropane; in the compounds of said formulae CF2?mClm=CCl-CHF2?nCln (Formula I), CF3?pClpCHCl=CH2Cl (Formula II), and CF3?xClxCF2?yClyCHF2?zClz (Formula III), m=0, 1, 2; n=1, 2; p=2, 3; x=1, 2, 3; y=1, 2; z=1, 2 and 4?x+y+z?6; (b) the 1,2,3-trichloro-3,3-difluoropropene, 1,2,3-trichloro-1,1,2-trifluoropropane and 1,2,3-trichloro-1,1,3-trifluoropropane undergo dechlorination, producing 3-chloro-3,3-difluoropropyne, 3-chloro-2,3,3-trifluoropropene and 3-chloro-1,3,3-trifluoropropene; and (c) the 3-chloro-3,3-difluoropropyne, 3-chloro-2,3,3-trifluoropropene and 3-chloro-1,3,3-trifluoropropene are reacted with hydrogen fluoride, simultaneously yielding 1

Abstract: The present invention relates to bicyclic himbacine derivatives of the formula or a pharmaceutically acceptable salt thereof wherein: R1 is —[C(Ra)(Rb)]x—[C(Rb)(Rb)]y—C(O)NH2, or —N(H)—[(CH2)]z—C(O)—NH2, W is and the remaining variables are described herein. The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ASC, secondary prevention of myocardial infarction or stroke, or PAD.

Abstract: A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to bicyclic himbacine derivatives of the formula or a pharmaceutically acceptable salt thereof wherein: R1 is W is and the remaining variables are described herein. The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ASC, secondary prevention of myocardial infarction or stroke, or PAD.